Posted by Michael Wonder on 18 Dec 2022
Apellis submits marketing authorisation application to the EMA for pegcetacoplan for geographic atrophy
16 December 2022 - Apellis Pharmaceuticals today announced that the company has submitted a marketing authorisation application to the European Medicines Agency for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy secondary to age-related macular degeneration.
The submission is based on results from the Phase 3 DERBY and OAKS trials at 24 months.
